By William Bryant

Many clinical trial delays are blamed on regulatory approvals, site activation timelines, or patient recruitment challenges. However, one of the most overlooked causes of study delays is inadequate clinical supply planning. In many organizations, clinical supply strategy is developed after protocol finalization and sometimes even after site activation begins, creating operational risk that can delay first patient in, increase costs, and disrupt enrollment timelines. Integrating clinical supply strategy into study start-up planning is not simply a logistics improvement – it is a strategic operational requirement for modern clinical development programs.

Industry research has shown that operational inefficiencies, including supply chain issues, contribute significantly to clinical trial delays and increased development costs.^1,2 While much attention has been placed on patient recruitment and regulatory timelines, the impact of clinical supply planning on study timelines has received comparatively less attention. This article examines the risks associated with delayed clinical supply planning and proposes a model in which clinical supply strategy is integrated into study start-up activities from the earliest stages of protocol development.

Clinical Supply Planning In The Traditional Study Model

In many organizations, clinical supply planning follows a traditional sequential model in which protocol development, feasibility, regulatory submissions, and site activation planning occur before supply teams become fully engaged. Under this model, supply teams often receive the final protocol after timelines have already been established and commitments have already been made regarding study start dates and enrollment timelines.

This sequential approach creates several operational challenges. Clinical supply teams must develop demand forecasts under compressed timelines, comparator sourcing may become difficult due to availability or import restrictions, packaging and labeling timelines may be compressed, and distribution planning may be rushed. Manufacturing slots may not be available when needed, and packaging vendors may not be able to meet aggressive timelines. By the time supply teams are fully engaged, clinical operations timelines are already committed, leaving little opportunity to address supply chain risks.

This reactive model creates one of the most overlooked bottlenecks in clinical trial execution. While study teams often focus on regulatory approval timelines or site activation metrics, delays caused by supply chain planning can be equally significant but less visible until they directly impact study timelines.

Key Takeaways:

• Engage clinical supply teams during protocol review and feasibility assessments.
• Identify risks in sourcing, packaging, and distribution early.
• Align supply planning timelines with site activation and enrollment schedules.
• Communicate cross-functionally to ensure timelines are realistic and achievable.

Clinical Supply Planning As A Strategic Function

Clinical supply planning should be considered a strategic function rather than a logistical task. Supply strategy decisions influence study timelines, budgets, site activation schedules, and patient enrollment timelines. Decisions related to manufacturing quantities, comparator sourcing, packaging strategy, depot locations, and resupply models all have direct implications for study execution.

Demand forecasting is one of the most critical components of clinical supply planning. Accurate forecasting requires collaboration between clinical operations, biostatistics, and clinical supply teams. Forecasting models typically consider the number of countries, number of sites, enrollment rate assumptions, screening failure rates, randomization ratios, visit schedules, treatment duration, dropout rates, replacement patients, and buffer stock requirements. Without accurate forecasting, studies often either overproduce or underproduce drug product, increasing costs or causing drug shortages and enrollment delays. This is particularly critical for biologics and advanced therapies, where manufacturing costs are high.³

Comparator and ancillary supply sourcing also present significant challenges. Many clinical trials require comparator drugs, rescue medications, background therapies, or ancillary supplies such as lab kits and medical devices. Comparator sourcing can take several months, especially when drugs must be sourced internationally, when import/export regulations apply, or when blinding and over-encapsulation are required. If comparator sourcing is not initiated early in the study timeline, site activation and patient enrollment may be delayed.

Packaging and labeling timelines are also frequently underestimated. Label text must include country-specific regulatory language, expiry dates, storage conditions, kit numbers, and randomization information. For global trials, labels must be translated and approved in multiple countries. Packaging timelines must also account for manufacturing schedules, quality release timelines, and distribution schedules. Delays in packaging and labeling are a common cause of delays in site activation and first patient enrollment.

Key takeaways:

• Engage early with clinical operations, biostatistics, and vendors during study start-up.
• Collaborate proactively on forecasting, comparator sourcing, and labeling.
• Identify and mitigate operational risks before timelines are finalized.
• Reduce the likelihood of drug shortages, emergency shipments, or study delays.

Distribution Strategy And Inventory Management

Global clinical trials require complex distribution strategies that may involve central depots, regional depots, direct-to-site shipping, or hybrid distribution models. Distribution planning must consider country import/export regulations, temperature-controlled shipping requirements, depot storage capacity, shipment lead times, customs clearance timelines, and inventory management systems. Depot selection and distribution strategy should be planned during study start-up rather than after site activation begins.

Resupply strategy is another critical component of clinical supply planning. Common resupply models include push models, pull models, just-in-time supply models, and predictive resupply models based on enrollment data. A poor resupply strategy can lead to sites running out of drug, emergency shipments, temperature excursions, enrollment holds, and protocol deviations. Inventory management systems and interactive response technology systems must be configured early to support resupply strategy and inventory tracking.

When clinical supply planning is not integrated into study start-up, common issues include first-patient-in delays, sites activated without drug available, emergency shipments, drug shortages, temperature excursions, expired drug at sites, protocol deviations due to supply issues, increased study costs, timeline extensions, and audit or inspection findings. Industry data suggest that a significant percentage of clinical trials experience delays due to operational and supply chain issues.² Clinical trial delays can cost sponsors millions of dollars per day in delayed product launch revenue.⁴

Key takeaways:

• Define depot locations early in study start-up.
• Configure inventory management systems to support resupply strategy.
• Align resupply models with enrollment projections.
• Prevent first-patient-in delays, emergency shipments, and protocol deviations.
• Ensure smooth trial execution across all sites.

Integrated Study Start-Up And Clinical Supply Model

A more effective approach is an integrated model in which clinical supply strategy is incorporated into study start-up from the beginning of protocol development. Instead of operating sequentially, clinical operations and clinical supply teams should work in parallel throughout the start-up phase.

Traditional Model (Sequential): Protocol → feasibility → regulatory → site activation → supply planning → manufacturing → distribution → first-patient-in

Integrated Model (Parallel): Protocol development, feasibility, supply forecasting, comparator sourcing, packaging strategy, depot strategy, regulatory start-up, site activation, distribution planning → first-patient-in

The integrated model reduces risk because supply planning activities occur simultaneously with feasibility and regulatory start-up rather than after them.

Key takeaways:

• Identify potential bottlenecks early in study start-up.
• Align timelines across clinical operations, supply, and other functions.
• Coordinate sourcing, packaging, and distribution before site activation.
• Prevent delays and ensure first-patient-in occurs as planned.

Real-World Operational Example

Consider a global Phase 3 clinical trial planned across the United States, Europe, and Asia. The clinical operations team developed aggressive enrollment timelines and initiated feasibility and site selection activities. However, clinical supply planning began only after the protocol was finalized and regulatory submissions were underway.

The study required comparator drug sourcing from multiple countries, over-encapsulation for blinding, multi-language labeling, and temperature-controlled distribution through regional depots. Comparator sourcing took longer than expected due to limited availability in certain regions. Label translations and regulatory approvals for labeling took several months. Packaging timelines were delayed due to manufacturing slot availability.

As a result, several sites were activated before drug was available for shipment. Emergency shipments were required, increasing costs significantly. First-patient-in was delayed by approximately eight weeks, and enrollment timelines had to be adjusted.

If clinical supply planning had been initiated during protocol development and feasibility planning, comparator sourcing could have started earlier, labeling timelines could have been incorporated into start-up timelines, and depot strategy could have been finalized before site activation. This example illustrates how delayed supply planning can directly impact study timelines even when regulatory approvals and site activation activities are completed on time.

Key takeaways:

• Engage clinical supply teams early in protocol development and feasibility.
• Initiate comparator sourcing, labeling, and depot strategy before site activation.
• Maintain enrollment timelines and reduce operational risk.
• Ensure first-patient-in occurs on schedule.

Cross-Functional Collaboration

Clinical supply strategy requires collaboration across multiple functional groups, including clinical operations, clinical supply chain teams, regulatory affairs, quality assurance, manufacturing, packaging and labeling vendors, depots and logistics vendors, interactive response technology vendors, data management, and biostatistics. Clinical trials are cross-functional programs, and supply strategy cannot operate in isolation. Organizations that integrate supply strategy into start-up planning demonstrate improved timelines, fewer operational delays, and improved study execution.⁵

Key takeaways:

• Establish cross-functional teams early in study start-up.
• Align clinical supply, operations, and vendor activities.
• Promote clear communication and shared responsibilities.
• Identify risks proactively, prevent delays, and ensure smooth execution across all sites.

Conclusion

Clinical trial delays are often attributed to regulatory approvals or patient recruitment challenges, but clinical supply planning is one of the most overlooked causes of study delays. Clinical supply strategy should not be treated as a downstream operational task. Instead, it should be integrated into study start-up from protocol development through site activation planning.

Early integration of clinical supply teams improves forecasting accuracy, reduces operational risk, prevents drug shortages, and ensures that investigational product is available when sites are ready to enroll patients. In modern clinical development, clinical supply strategy is not simply a logistics function; it is a critical component of study start-up strategy and overall trial success.

Organizations that integrate clinical supply planning early will see improved timelines, reduced costs, and more successful clinical trial execution. As clinical trials become increasingly global and complex, integrating clinical supply strategy into study start-up planning will become not only beneficial but necessary for efficient and successful clinical development programs.

Make early integration of clinical supply a standard part of study start-up. Establishing supply planning during protocol development, feasibility, and site activation ensures product availability, reduces delays, controls costs, and supports seamless execution across global trials.

References:

1. Getz, K. A., Campo, R. A., & Kaitin, K. I. (2015). Variability in protocol design complexity by phase and therapeutic area. Drug Information Journal.
2. Tufts Center for the Study of Drug Development. (2020). Impact of clinical trial delays on drug development timelines and costs.
3. McKinsey & Company. (2021). Clinical supply chain optimization in clinical development.
4. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33.
5. TransCelerate BioPharma Inc. (2017). Clinical trial start-up metrics and benchmarking report.

About The Author:

William Bryant is a clinical research professional with over 20 years of experience in global clinical trial operations, study start-up, and clinical development strategy. He has worked across Phase 1 through Phase 3 clinical trials in multiple therapeutic areas including oncology, CNS, infectious disease, and metabolic disorders. His experience includes study start-up strategy, site selection and feasibility, regulatory start-up, clinical operations leadership, and cross-functional program management. His professional focus includes improving clinical trial efficiency, reducing study start-up timelines, and integrating operational strategy across clinical development programs.